This activity is expired and is no longer available for CME credit.


Impact and Relevance of Adherence to Interferons in Multiple Sclerosis

Author(s)/Faculty: Aaron Boster, MD; Guy J. Buckle, MD, MPH; Lynn Stazzone, RN, MSN, NP, MSCN; Patricia Kennedy, RN, CNP, MSCN
Release Date: 5/2/2014Expiration Date: 11/12/2016
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
Relapsing-remitting multiple sclerosis (RRMS) is a chronic disease affecting about 400,000 people in the United States characterized by increasing patient disability and burden on society. While there is no cure for multiple sclerosis (MS), pharmaceutical treatments exist that can limit the number of relapses a patient experiences, and slow disease progression. One such class of agents used to treat RRMS are the interferons: interferon-beta-1a and interferon-beta-1b. Patients must take these injectable medications regularly to achieve the optimal outcomes. However, patient issues and potential adverse effects of medications lower adherence. This CME program will review these challenges, enabling providers to apply practical strategies to enhance adherence to these treatments.